Equities research analysts expect GW Pharmaceuticals PLC- (NASDAQ:GWPH) to report earnings per share of ($2.39) for the current quarter, Zacks reports. Two analysts have made estimates for GW Pharmaceuticals PLC-‘s earnings, with the highest EPS estimate coming in at ($2.13) and the lowest estimate coming in at ($2.64). GW Pharmaceuticals PLC- posted earnings of ($2.18) per share during the same quarter last year, which indicates a negative year over year growth rate of 9.6%. The business is expected to report its next quarterly earnings report on Monday, December 3rd.
According to Zacks, analysts expect that GW Pharmaceuticals PLC- will report full-year earnings of ($9.19) per share for the current year, with EPS estimates ranging from ($10.32) to ($8.26). For the next financial year, analysts forecast that the firm will report earnings of ($6.94) per share, with EPS estimates ranging from ($9.12) to ($2.28). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that cover GW Pharmaceuticals PLC-.
GW Pharmaceuticals PLC- (NASDAQ:GWPH) last posted its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($1.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.40) by $1.14. The firm had revenue of $3.46 million for the quarter, compared to analyst estimates of $2.00 million. GW Pharmaceuticals PLC- had a negative net margin of 1,392.61% and a negative return on equity of 47.65%.
GWPH traded down $5.23 on Friday, reaching $151.72. 739,035 shares of the company’s stock were exchanged, compared to its average volume of 441,956. The firm has a market capitalization of $4.80 billion, a PE ratio of -21.83 and a beta of 2.61. GW Pharmaceuticals PLC- has a twelve month low of $101.07 and a twelve month high of $179.65. The company has a current ratio of 8.67, a quick ratio of 8.21 and a debt-to-equity ratio of 0.01.
A number of large investors have recently bought and sold shares of GWPH. WealthTrust Fairport LLC acquired a new position in GW Pharmaceuticals PLC- in the 1st quarter valued at about $104,000. Stratos Wealth Partners LTD. boosted its holdings in GW Pharmaceuticals PLC- by 216.0% in the 1st quarter. Stratos Wealth Partners LTD. now owns 948 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 648 shares during the last quarter. Flagship Harbor Advisors LLC acquired a new position in GW Pharmaceuticals PLC- in the 2nd quarter valued at about $109,000. Envestnet Asset Management Inc. acquired a new position in GW Pharmaceuticals PLC- in the 2nd quarter valued at about $119,000. Finally, Cowen Prime Services LLC boosted its holdings in GW Pharmaceuticals PLC- by 708.0% in the 2nd quarter. Cowen Prime Services LLC now owns 1,010 shares of the biopharmaceutical company’s stock valued at $141,000 after purchasing an additional 885 shares during the last quarter. Institutional investors own 75.44% of the company’s stock.
GW Pharmaceuticals PLC- Company Profile
GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development.
Recommended Story: Marijuana Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.